AMENDMENTS TO THE CLAIMS

1. (Previously amended) A compound having the formula (I):



(I)

and salts thereof;

wherein R is:



;

wherein X and X" are independently selected from C=O, C=S, C=NH, $C=NR^X$, S=O or SO_2;

wherein n is 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is $X"R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is H, NH_2, NHR^A, NR^AR^B, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^A and R^B are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

provided that when B is H and X is C=O, then A is other than

(a) a pyridinyl ring substituted with a single $NHC(O)R^D$ substitutent or

(b) a (C_5-C_6) saturated cycloalkyl ring substituted with a single $NHC(O)R^D$ substitutent, wherein R^D is (C_1-C_{17}) unsubstituted alkyl or (C_2-C_{17}) unsubstituted alkenyl;

wherein R^1 is



;

wherein X' and X"' are independently selected from C=O, C=S, C=NH, $C=NR^{X'}$, S=O or SO_2;

wherein m is 0 or 1;

wherein $R^{X'}$ is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is $X"'R^{Y'}$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{Y'}$ is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH_2, $NHR^{A'}$, $NR^{A'}R^{B'}$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50}-R^{53} is independently selected from C_1-C_{15} alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is



wherein K and K' together form a C_3-C_7 cycloalkyl or heterocyclyl ring or a C_5-C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,


and

;

wherein each of R^{24}, R^{25}, and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are indcpendently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R^{17}, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18}, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and


; or

wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,


,

wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.

2. (Previously amended) A compound having the formula (I):



(I)

and salts thereof;

wherein R is:



;

wherein X and X" are independently selected from C=O, C=S, C=NH, $C=NR^X$, S=O or SO_2;

wherein n is 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is $X"R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl,

heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is aryl;

provided that when B is H and X is C=O, then A is other than a phenyl ring substituted with either:

(a) –O-((C_8-C_{15}) unsubstituted alkyl), wherein said phenyl ring may be further optionally substituted with one substituent selected from halo, nitro, (C_1-C_3) alkyl, hydroxyl, (C_1-C_3) alkoxy or (C_1-C_3) alkylthio; or

(b) –NHC(O)R^D, wherein the phenyl ring may be further optionally substituted with 1-2 substituents independently selected from amino, nitro, (C_1-C_3) alkyl, hydroxyl, (C_1-C_3) alkoxy, halo, mercapto, (C_1-C_3) alkylthio, carbamyl or (C_1-C_3) alkylcarbamyl, wherein R^D is (C_1-C_{17}) unsubstituted alkyl or (C_2-C_{17}) unsubstituted alkenyl;

wherein R^1 is



;

wherein X' and X''' are independently selected from C=O, C=S, C=NH, C=$NR^{X'}$, S=O or SO_2;

wherein m is 0 or 1;

wherein $R^{X'}$ is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is X''$R^{Y'}$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{Y'}$ is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH_2, $NHR^{A'}$, $NR^{A'}R^{B'}$, alkyl, alkenyl, alkynyl, alkoxy,

aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50}-R^{53} is independently selected from C_1-C_{15} alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is



wherein K and K' together form a C_3-C_7 cycloalkyl or heterocyclyl ring or a C_5-C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,


and

;

wherein each of R^{24}, R^{25}, and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R^{17}, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18}, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and


; or

wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,


,

wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.

Claims 3-4 (Withdrawn)

5. (Currently amended) The compound according to ~~either of claims~~ claim 1 ~~or 2~~, wherein R is selected from the group consisting of:


,

,


,

and

;

wherein each of R^3, R^4, R^5, and R^6 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R^{200} is selected from the group consisting of hydrido, ~~aryl~~, heterocyclyl, and heteroaryl.

6. (Currently amended) The compound according to claim 5, wherein R is selected from


and

;

and wherein $R^{4'}$ is selected from the group consisting of ~~substituted phenyl,~~ heteroaryl, and heterocyclyl.

7. (Currently amended) The compound according to claim 6, wherein R is ~~selected from the group consisting of~~





~~wherein X^3 is chloro or trifluoromethyl and wherein q is 0~~



8. (Previously amended) The compound according to either of claims 1 or 2, wherein R^1 is selected from the group consisting of:



wherein R^8 is selected from a natural amino acid side chain or an amino acid side chain that is not naturally occurring;

wherein each of R^9, R^{10} and R^{11} is selected from hydrido, alkyl, aryl, heterocyclyl and heteroaryl;

wherein R^{12} is selected from the group consisiting of heterocyclyl, heteroaryl, aryl, and alkyl and

wherein R^{13} is selected from (C_1-C_3-alkyl) and aryl.

C3

9. (Currently amended) The compound according to claim 8, wherein R^1 is selected from the group consisting of:





, and



;

wherein R^8 is selected from tryptophan side chain and lysine side chain;

wherein each of R^{10} and R^{11} is independently selected from hydrido and alkyl;

wherein R^{12} is selected from imidazolyl, N-methylimidazolyl, indolyl, quinolinyl, benzyloxybenzyl, and benzylpiperidenylbenzyl; and

wherein ~~X~~ X^4 is selected from fluoro, and trifluoromethyl.

10. (Previously amended) The compound according to either of claims 1 or 2, wherein J is selected from the group consisting of hydrido, amino, azido and



;

wherein R^{17} and R^{18} taken together form a group selected from ketal,

 and  ;

or wherein R^{17} is hydroxyl when R^{18} is hydrido;

or wherein J, together with R^{17}, forms a heterocyclyl ring.

11. (Original) The compound according to claim 10, wherein R^2 is selected from the group consisting of

 and  ;

wherein R^{17} and R^{18} taken together form a group selected from

 and  , wherein R^{22} is selected from the group consisting of H and alkyl; and wherein R^{19} is selected from the group consisting of hydrido, amino, azido and  .

12. (Original) The compound acccording to claim 11, wherein R^2 is



Claims 13-14 (Cancelled)

15. (Previously amended) A pharmaceutical composition comprising the compound according to either of claims 1 or 2 and a pharmaceutically acceptable carrier.

Claims 16-22 (Withdrawn)

23. (Currently amended) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of penicillins ~~and related drugs~~, carbapenems, cephalosporins ~~and related drugs~~, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents ~~including sulfonamides~~, trimethoprim ~~and its combinations and~~, pyrimethamine, synthetic antibacterials ~~including nitrofurans, methenamine mandelate and methenamine hippurate~~, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, ~~everninomycin,~~ everninomicin, glycopeptide, ~~glycylcycline,~~ glycylcycline, ketolides, ~~oxazolidinone;~~ oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, Ziracin (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-

hexopyranosyl)flambamycin), LY333328 (oritavancin), ~~CL-331002, HMR3647~~, Linezolid (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), Synercid (dalfopristin-quinupristin), Aztreonam (2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl] amino]-2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), Metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol), Epiroprim (5-[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-2,4-pyrimidinediamine), OCA-983 (1-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253 (trinem), Sanfetrinem ~~sodium~~ ((1S, 5S, 8aS, 8bR)-1, 2, 5, 6, 7, 8, 8a, 8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-834 ((4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5-oxo-3-pyrrolidinyl]thio]-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), Biapenem (6-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6, 7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), ~~A-99058.1, A-165600, A-179796,~~ KA 159 (stipiamide), Dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13, 14-hexahydro-6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-[3]hexene[1,5]diynonaphtho[2,3-c]phenanthridine-2-carboxylic acid), DX8739 ((4R,5S,6S)-3-[[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-oxopentyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid), Cefluprenam ((2E)-N-(2-amino-2-oxoethyl)-3-[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoro methoxy)imino]acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-en-3-yl]-

N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), Cefoselis ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), Sanfetrinem celexetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl] oxy]ethyl ester), ~~HGP-31~~, Cefpirome (1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), ~~Mersacidin~~, KP 736 ((6R,7R)- 7-[[(2Z)-(2-amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy] imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin VIII), ~~Kosan, AM 1732~~, MEN 10700 ((5R,6S)-3-[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), Lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3'S,4S)-[2,3'-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), NE-1530 (3'-sialyllacto-N-neotetraose), PR 39 (L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-

prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolinamide [SEQ ID NO; 1]), K130 (5-[[4-[3-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl] methyl]-2,4-pyrimidinediamine), ~~OPC 20000, OPC 2045, Veneprim,~~ PD 138312 ((R)- 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), CP 111905 (5-deoxy-5-[[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene-D-neo-inositol), Sulopenem ((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-[[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788 ((6R,7R)- 7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3'R)-1'-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt), ~~Cyclothialidine,~~ Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28, 29,41,42-octadecahydro-41-hydroxy-12,45-bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nonaoxo-18H,27H-5a,29-(iminoethaniminoethanimino ethaniminoethanimino[7,2]quinolinomethanoxy methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1',5':1,6]pyrido [3,2-

cl cont.

m][1,11,17,24,4,7,20, 27]tetrathiatetraazacyclotriacontin-1-yl]carbonyl]-2,3-didehydroalanyl-2,3-didehydro-alanine methyl ester stereoisomer), ~~SEP 132613,~~ micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-(hydroxy-.kappa.O)-6-pentylphenyl]-4-thiazolyl-.kappa.N3]-3-methyl-4-thiazolidinyl-.kappa.N3]-2-(hydroxy-.kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-thiazolecarboxylato(2-)-.kappa.N3, .kappa.O4]-Zinc), ~~SB 275833,~~ SR-15402 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), ~~SUN A0026,~~ TOC 39 (1-(2-amino-2-oxoethyl)-4-[[(1E)-2-[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-[2-[[(2S,3S)-2-[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidinyl]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), Cefozopran (1-[[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt), Cefetamet pivoxil ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), and T 3811 (des-F(6)-quinolone).

Claims 24-26 (Withdrawn)

27. (Previously amended) The compound of claim 1 having the formula (II):



(II)

wherein R^{56} is an optionally substituted straight-chain C_8-C_{14} alkyl group.

Claims 28-29 (Withdrawn)

30. (Previously amended) A method of using the compound according to claim 27 to make a compound according to either of claims 1 or 2.

31. (Previously added) The compound according to either of claims 1 or 2 wherein said compound is selected from

Cpd #	R	R^1	R^2
1	$NHCONH(CH_2)_7CH_3$	NH_2	

2	$NHCONH(CH_2)_{11}CH_3$	NH_2	
3	$NHCONH(CH_2)_{10}CH_3$		
5			
17	$NHCONH(CH_2)_{11}CH_3$		
48	$NHCONH(CH_2)_{10}CH_3$	NH_2	
56	$NHCONH(CH_2)_7CH_3$		
57	$NHCONH(CH_2)_{10}CH_3$		
58	$NHCONH(CH_2)_{11}CH_3$		
62	$NHCONH(CH_2)_7CH_3$		
63	$NHCONH(CH_2)_{10}CH_3$		
64	$NHCONH(CH_2)_{11}CH_3$		
69	$NHCONH(CH_2)_7CH_3$		
70	$NHCONH(CH_2)_7CH_3$		

71	$NHCONH(CH_2)_7CH_3$		
75	$NHCONH(CH_2)_{10}CH_3$		
76	$NHCONH(CH_2)_7CH_3$		
77	$NHCONH(CH_2)_7CH_3$		
78	$NHCONH(CH_2)_7CH_3$		
87	$NHCONH(CH_2)_{11}CH_3$		
88	$NHCONH(CH_2)_{11}CH_3$		
89	$NHCONH(CH_2)_{11}CH_3$		
108	$NHCONH(CH_2)_{10}CH_3$		
113	$NHCONH(CH_2)_{10}CH_3$		
114	$NHCONH(CH_2)_{10}CH_3$		
117	$NHCONH(CH_2)_8CH_3$	NHBoc	
118	$NHCONH(CH_2)_8CH_3$	NH_2	
119	$NHCONH(CH_2)_9CH_3$	NHBoc	

120	$NHCONH(CH_2)_9CH_3$	NH_2	

32. (Previously added) The compound according to claim 31 wherein said compound is selected from

Cpd #	R	R^1	R^2
2	$NHCONH(CH_2)_{11}CH_3$	NH_2	
3	$NHCONH(CH_2)_{10}CH_3$		
48	$NHCONH(CH_2)_{10}CH_3$	NH_2	
89	$NHCONH(CH_2)_{11}CH_3$		
118	$NHCONH(CH_2)_8CH_3$	NH_2	
120	$NHCONH(CH_2)_9CH_3$	NH_2	

33. (New) The compound according claim 2, wherein R is selected from the group consisting of:



and



;

wherein each of R^3 and R^5 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R^{200} is aryl.

34. (New) The compound according to claim 33, wherein R is



;

and wherein $R^{4'}$ is selected from the group consisting of substituted phenyl.

35. (New) The compound according to claim 34, wherein R is



;

and wherein X^3 is chloro or trifluoromethyl.

36. (New) The method according to claim 23, wherein anti-folate agents are sulfonamides or synthetic antibacterials are sclccted from nitrofurans, methenamine mandelate and methenamine hippurate.